Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo
Objective: Long-acting glucagon-like peptide-1 receptor agonists (GLP-1RAs), like liraglutide and semaglutide, are viable treatments for diabetes and obesity. Liraglutide directly activates hypothalamic proopiomelanocortin (POMC) neurons while indirectly inhibiting Neuropeptide Y/Agouti-related pept...
Guardado en:
Autores principales: | Yanbin Dong, Jamie Carty, Nitsan Goldstein, Zhenyan He, Eunsang Hwang, Dominic Chau, Briana Wallace, Anita Kabahizi, Linh Lieu, Yunqian Peng, Yong Gao, Ling Hu, J. Nicholas Betley, Kevin W. Williams |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4ec2aa488f164583b0cbb499e20a9df9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021) -
Corrigendum: Safety of Semaglutide
por: Mark M. Smits, et al.
Publicado: (2021) -
Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype
por: Toomas Jagomäe, et al.
Publicado: (2021) -
Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh RA, et al.
Publicado: (2020) -
Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)